In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vera Hirsh discusses how, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR-positive non-small cell lung cancer (NSCLC).
Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung
© 2017 Imedex, LLC.